Abstract
Randomized, double-blind trials on new treatments, including anakinra, etanercept, infliximab, and leflunomide, show convincing reduction in radiographic progression. The relative efficacy of these new treatments is unknown. Head-to-head comparisons have not been performed and comparing treatment arms across trials has several pitfalls. These possible pitfalls are discussed.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antirheumatic Agents / therapeutic use*
-
Arthritis, Rheumatoid / diagnostic imaging*
-
Arthritis, Rheumatoid / drug therapy*
-
Clinical Trials as Topic
-
Disease Progression
-
Etanercept
-
Humans
-
Immunoglobulin G / therapeutic use
-
Infliximab
-
Interleukin 1 Receptor Antagonist Protein
-
Isoxazoles / therapeutic use
-
Leflunomide
-
Radiography
-
Receptors, Tumor Necrosis Factor / therapeutic use
-
Severity of Illness Index
-
Sialoglycoproteins / therapeutic use
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antirheumatic Agents
-
IL1RN protein, human
-
Immunoglobulin G
-
Interleukin 1 Receptor Antagonist Protein
-
Isoxazoles
-
Receptors, Tumor Necrosis Factor
-
Sialoglycoproteins
-
Infliximab
-
Leflunomide
-
Etanercept